0.02
-25.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Revive Therapeutics
Its shares trade on Canadian Securities Exchange under the ticker RVV.CN. It has been listed since 12 July 2013.
Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. The company is headquartered in Toronto, Ontario. The company went IPO on 2013-07-12. The firm is focused on the research and development of therapeutics for rare disorders and infectious diseases. The firm is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Jul 2013
- Website
- revivethera.com ↗
Leadership
Pay as last reported
- Mr. Michael FrankExecutive Chairman of the Board, Chief Executive Officer, since 2019C$360,000
- Mr. Carmelo MarrelliChief Financial Officer, Corporate SecretaryC$130,110
- Mr. Joshua HermanIndependent DirectorC$349,658
- Mr. William JacksonIndependent DirectorC$349,658
- Mr. Andrew LindzonIndependent DirectorC$349,658
- Mr. Christian ScovennaIndependent DirectorC$349,658
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Revive Therapeutics Ltd. has FDA orphan drug status for CBD to treat autoimmune hepatitis and organ transplant injuries.
- Revive Therapeutics Ltd. focuses on rare inflammatory diseases with a cannabinoid pharmaceutical portfolio.
- Revive Therapeutics Ltd. explores Bucillamine for severe influenza and COVID-19 treatment.
Weaknesses
- Revive Therapeutics Ltd. is a small company with limited resources for drug development.
- Revive Therapeutics Ltd. has no commercialized products yet in the market.
- Revive Therapeutics Ltd. relies on a single subsidiary for psilocybin-based therapeutics.
Opportunities
- Revive Therapeutics Ltd. can expand its cannabinoid portfolio for rare diseases in the Health Care sector.
- Revive Therapeutics Ltd. may benefit from increased interest in cannabinoid therapies for inflammatory conditions.
- Revive Therapeutics Ltd. could leverage FDA orphan drug status for additional rare disease treatments.
Threats
- Revive Therapeutics Ltd. faces competition from larger pharmaceutical companies in the Health Care sector.
- Revive Therapeutics Ltd. must navigate regulatory challenges for cannabinoid-based therapies.
- Revive Therapeutics Ltd. is exposed to market volatility in the cannabis industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.